Browsing Tag
Dr. David Reardon
1 post
Immunomic Therapeutics begins ITI-1001 Phase 1 trial in glioblastoma
Immunomic Therapeutics, Inc., a clinical-stage biotech company specializing in nucleic acid immunotherapy platforms, has dosed the first patient…